Health Care & Life Sciences » Pharmaceuticals | Eyegate Pharmaceuticals Inc.

Eyegate Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
669.30
407.50
1,652.50
Cost of Goods Sold (COGS) incl. D&A
5.50
1.70
1.30
-
-
-
Gross Income
5.50
1.70
1.30
-
-
-
SG&A Expense
3,092.50
2,460.40
6,676.40
14,010.90
14,856.40
12,458.70
EBIT
3,097.90
2,462.10
6,677.60
-
14,468.20
10,844.70
Unusual Expense
-
1,335.30
223.20
-
91.10
-
Non Operating Income/Expense
-
-
0.00
-
-
-
Interest Expense
611.40
441.70
1,934.50
0.30
1.20
1
Pretax Income
3,707.10
1,567.40
8,388.00
13,343.40
14,559.90
10,725.40
Income Tax
24.50
15.90
-
-
1,342.00
86
Consolidated Net Income
3,682.60
1,551.50
8,388.00
13,343.40
13,217.90
10,811.40
Net Income
3,879.40
1,774.00
8,393.10
13,343.40
13,217.90
10,811.40
Net Income After Extraordinaries
3,879.40
1,774.00
8,393.10
13,343.40
13,217.90
10,811.40
Net Income Available to Common
3,879.40
1,774.00
16,615.20
13,343.40
13,217.90
10,811.40
EPS (Basic)
0.22
0.10
2.70
1.51
0.93
0.30
Basic Shares Outstanding
17,604.80
17,604.80
6,164.10
8,833.90
14,260.10
35,483.70
EPS (Diluted)
0.22
0.10
2.70
1.51
0.93
0.30
Diluted Shares Outstanding
17,604.80
17,604.80
6,164.10
8,833.90
14,260.10
35,483.70
EBITDA
3,092.40
2,460.40
6,676.40
13,341.70
14,448.90
10,806.20
Non-Operating Interest Income
2.20
1.10
0.90
3.70
0.60
120.40
Minority Interest Expense
196.90
222.50
5.20
-
-
-
Preferred Dividends
-
-
8,222.00
-
-
-

About Eyegate Pharmaceuticals

View Profile
Address
271 Waverley Oaks Road
Waltham Massachusetts 02452
United States
Employees -
Website http://www.eyegatepharma.com
Updated 07/08/2019
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel (OBG). OBG is a topically-applied eye drop formulation that is being developed under the 510k De Novo path for devices submitted for marketing clearance to the U.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.